Brief: Clarity Pharmaceuticals Says Patent Application Granted In China
12/09/2022 09:17
Sept 12 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* PATENT APPLICATION COVERING CO'S OPTIMISED PROSTATE
SPECIFIC
MEMBRANE ANTIGEN TARGETING AGENT, SAR-BISPSMA GRANTED IN CHINA
Source text for Eikon: ID:nASX3j0yhR
Further company coverage: CU6.AX
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial